BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lytix Biopharma Closes $10.4 Million Funding Round


1/22/2009 6:18:43 AM

TROMS0, Norway, January 22 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma today announced the closure of a successful funding round to a total value of 73 million NOK (US$ 10.4 million), the proceeds of which will fund the early-stage clinical development of two novel drugs.

Lytix develops novel lytic peptide drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments - both areas with high unmet medical needs. The Company was established in 2003 to commercialise world-class research in the field of lytic peptides, having spun out by scientists working in the University Hospital and University of Tromso in Norway.

Lytix Biopharma CEO Gunnar Saelid commented, "The Company has made significant progress in the last year, initiating full preclinical development activities for two important projects. LTX-109 is a novel antimicrobial compound that is effective against a broad range of pathogens. Indeed it is so effective, that although the initial formulation is for the treatment of skin infections, we envisage several other indications such as nail fungal infections, acne and oropharyngeal candidaisis. In oncology, LTX-315 (Oncopore(TM)) is a product aimed at the treatment of solid tumours, potentially in combination with existing therapies. Oncopore(TM) is currently in preclinical development and has proven efficacy across a range of 40 tumour cell lines, including lines resistant to established chemotherapy. In vivo studies in syngeneic mice demonstrate a potential for a rapid induction of tumour necrosis, and a complete and stable tumour response mediated by the immune-system. Both LTX-109 and LTX-315 will enter the clinical phases during the latter half of 2009."

In order to capitalise on the commercial potential that lies in this development pipeline, Lytix has successfully raised working capital through a shares issue totalling 73 million NOK to fund the early-stage clinical development. Chairman of Board, Knut Eidissen, added: "We are truly excited to be involved with such innovative projects - if we are successful we can potentially cure some very sick patients and save lives. It goes without saying that the commercial upside is significant for a company like ours, which aims to outlicense rights and form joint-venture partnerships with larger pharmaceutical companies. The interest shown in our company, even in these turbulent financial times, further strengthens our belief in the value of our pipeline."

Corporate Inquiries

Gunnar Saelid, CEO Lytix Biopharma AS P.O. Box 6447, Tromso Research Park, N-9294 Tromso, Norway Tel +47-911-92-330, Email: gunnar.salid@lytixbiopharma.com

Source: Lytix Biopharma AS

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES